Cellular and T cell engager Immunotherapy
Absolute lymphocyte count at Day 30 (not earlier) and early CRS predict delayed responses to teclistamab: Results from the US Myeloma Immunotherapy Consortium
Rahul Banerjee, MD
Assistant Professor, Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington, United States